During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

Northwestern Medicine scientists have uncovered a key pathway controlling tumor growth in B-cell lymphomas, according to a study published in the Journal of Clinical Investigation.

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

Scientists have discovered a novel subset of cancer-fighting immune cells that reside outside of their normal neighborhood -- known as the tertiary lymphoid structure -- where they become ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

B-cell lymphoma is a type of blood cancer that affects the B lymphocytes of the immune system. They usually arise in the lymph nodes or in other lymphoid tissue, such as the spleen, bone marrow ...

CAR T-cell therapy showed efficacy in relapsed large B-cell lymphoma across age groups, including patients 70 and 80 years or older.

Outpatient lymphodepletion followed by Tecartus was found to be safe and effective in treating B-cell acute lymphoblastic leukemia and mantle cell lymphoma.

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

T-cell lymphoma is a type of lymphatic cancer that starts in the T lymphocytes (T cells), a type of white blood cell. T lymphocytes (T cells) and B lymphocytes (B cells) are two types of white ...

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...